DK2016080T3 - Dihydropyrazolopyrimidinon-derivater - Google Patents

Dihydropyrazolopyrimidinon-derivater

Info

Publication number
DK2016080T3
DK2016080T3 DK07742843.1T DK07742843T DK2016080T3 DK 2016080 T3 DK2016080 T3 DK 2016080T3 DK 07742843 T DK07742843 T DK 07742843T DK 2016080 T3 DK2016080 T3 DK 2016080T3
Authority
DK
Denmark
Prior art keywords
dihydropyrazolopyrimidinon
derivatives
Prior art date
Application number
DK07742843.1T
Other languages
English (en)
Inventor
Toshihiro Sakamoto
Satoshi Sunami
Fuyuki Yamamoto
Kenji Niiyama
Makoto Bamba
Keiji Takahashi
Hidetomo Furuyama
Takeshi Sagara
Sachie Otsuki
Toshihide Nishibata
Takashi Yoshizumi
Hiroshi Hirai
Original Assignee
Banyu Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to JP2006124208 priority Critical
Application filed by Banyu Pharma Co Ltd filed Critical Banyu Pharma Co Ltd
Priority to PCT/JP2007/059408 priority patent/WO2007126122A1/en
Application granted granted Critical
Publication of DK2016080T3 publication Critical patent/DK2016080T3/da
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38655640&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2016080(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41621,2-Diazoles condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DK07742843.1T 2006-04-27 2007-04-25 Dihydropyrazolopyrimidinon-derivater DK2016080T3 (da)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2006124208 2006-04-27
PCT/JP2007/059408 WO2007126122A1 (en) 2006-04-27 2007-04-25 Dihydropyrazolopyrimidinone derivatives

Publications (1)

Publication Number Publication Date
DK2016080T3 true DK2016080T3 (da) 2010-11-22

Family

ID=38655640

Family Applications (2)

Application Number Title Priority Date Filing Date
DK07742851.4T DK2017278T3 (da) 2006-04-27 2007-04-25 Dihydropyrazolopyrimidinonderivat
DK07742843.1T DK2016080T3 (da) 2006-04-27 2007-04-25 Dihydropyrazolopyrimidinon-derivater

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK07742851.4T DK2017278T3 (da) 2006-04-27 2007-04-25 Dihydropyrazolopyrimidinonderivat

Country Status (39)

Country Link
US (4) US7935708B2 (da)
EP (2) EP2016080B1 (da)
JP (2) JP4513919B2 (da)
KR (1) KR101409161B1 (da)
CN (1) CN101432284B (da)
AR (1) AR060635A1 (da)
AT (1) AT475662T (da)
AU (1) AU2007244185B2 (da)
BR (1) BRPI0710081A2 (da)
CA (1) CA2650119C (da)
CR (1) CR10359A (da)
CY (1) CY1118526T1 (da)
DE (1) DE602007008085D1 (da)
DK (2) DK2017278T3 (da)
DO (1) DOP2007000084A (da)
EC (1) ECSP088812A (da)
ES (2) ES2348751T3 (da)
GT (1) GT200800211A (da)
HK (1) HK1132498A1 (da)
HN (1) HN2008001532A (da)
HR (2) HRP20100563T1 (da)
HU (1) HUE032987T2 (da)
IL (1) IL194367A (da)
LT (1) LT2017278T (da)
MA (1) MA30428B1 (da)
MX (1) MX2008013063A (da)
MY (1) MY145408A (da)
NO (1) NO341617B1 (da)
NZ (1) NZ571196A (da)
PE (1) PE20080695A1 (da)
PL (2) PL2016080T3 (da)
PT (2) PT2016080E (da)
RU (1) RU2437885C2 (da)
SI (2) SI2016080T1 (da)
SV (1) SV2009003060A (da)
TW (1) TWI409262B (da)
UA (1) UA96152C2 (da)
WO (2) WO2007126122A1 (da)
ZA (1) ZA200807748B (da)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20080695A1 (es) * 2006-04-27 2008-06-28 Banyu Pharma Co Ltd Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel
JP5411847B2 (ja) * 2007-04-25 2014-02-12 Msd株式会社 Polymorphs of dihydropyrazolopyrimidinone derivatives as WEEL kinase inhibitors
WO2008141385A1 (en) * 2007-05-21 2008-11-27 Biota Scientific Management Pty Ltd Viral polymerase inhibitors
WO2009054332A1 (ja) * 2007-10-23 2009-04-30 Banyu Pharmaceutical Co., Ltd. ピリドン置換ジヒドロピラゾロピリミジノン誘導体
ES2430053T3 (es) 2008-06-12 2013-11-18 Merck Sharp & Dohme Corp. Procedimiento para producir derivados de bicicloanilina
US8575179B2 (en) 2008-12-12 2013-11-05 Msd K.K. Dihydropyrazolopyrimidinone derivatives
WO2010076887A1 (en) * 2009-01-05 2010-07-08 Banyu Pharmaceutical Co.,Ltd. Predictive biomarkers useful for cancer therapy mediated by a wee1 inhibitor
JP2012518598A (ja) * 2009-02-25 2012-08-16 Msd株式会社 ピリミドピリミドインダゾール誘導体
WO2011027800A1 (en) * 2009-09-02 2011-03-10 Banyu Pharmaceutical Co.,Ltd. Use of biomarker(s) to identify a wee1 inhibitor responsive patient and methods of treating cancer mediated by dysfunctional or aberrant p53 via administration of a wee1 inhibitor
US8703779B2 (en) 2009-09-15 2014-04-22 Merck Sharp & Dohme Corp. Preparation of crystalline forms of dihydropyrazolopyrimidinone
WO2012074754A1 (en) 2010-11-16 2012-06-07 Array Biopharma Inc. Combination of checkpoint kinase 1 inhibitors and wee 1 kinase inhibitors
CN106278943B (zh) * 2011-04-27 2019-07-30 日本瑞翁株式会社 光学薄膜、聚合性化合物、聚合性组合物、高分子、光学各向异性体以及肼化合物
US8796289B2 (en) 2011-07-19 2014-08-05 Abbvie Inc. Pyridazino[4,5-D]pyrimidin-5(6H)-one inhibitors of kinases
WO2013039854A1 (en) 2011-09-15 2013-03-21 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer
JP2014530867A (ja) 2011-10-20 2014-11-20 アッヴィ・インコーポレイテッド キナーゼのピリドピリミジノン阻害剤
EP2817308B1 (en) * 2012-02-23 2016-09-07 AbbVie Inc. Pyridopyrimidinone inhibitors of kinases
WO2014062454A1 (en) * 2012-10-15 2014-04-24 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer
LT2925888T (lt) * 2012-11-28 2018-01-10 Merck Sharp & Dohme Corp. COMPOSITION AND METHODS OF CANCER TREATMENT
GB201306610D0 (en) * 2013-04-11 2013-05-29 Almac Discovery Ltd Pharmaceutical compounds
GB201322602D0 (en) 2013-12-19 2014-02-05 Almac Discovery Ltd Pharmaceutical compounds
PL3235505T3 (pl) * 2014-12-17 2020-11-16 Delta-Fly Pharma, Inc. A pharmaceutical composition for the treatment or palliative care of an elderly patient with or end-stage cancer
WO2016168638A1 (en) 2015-04-17 2016-10-20 Abbvie Inc. Indazolones as modulators of tnf signaling
UY36630A (es) 2015-04-17 2016-11-30 Abbvie Inc Moduladores tricíclicos de la señalización por tnf
UY36629A (es) 2015-04-17 2016-11-30 Abbvie Inc Indazolonas como moduladores de la señalización de tnf
PT3345907T (pt) * 2015-09-01 2020-06-23 Taiho Pharmaceutical Co Ltd Compostos de pirazolo[3,4-d]pirimidina ou sais dos mesmos
CN105130986B (zh) * 2015-09-30 2017-07-18 广州科擎新药开发有限公司 嘧啶或吡啶并吡啶酮类化合物及其应用
EP3368538A4 (en) * 2015-11-01 2019-06-12 The Regents of The University of Colorado, A Body Corporate Wee 1 kinase inhibitors and methods of making and using the same
GB201612092D0 (en) * 2016-07-12 2016-08-24 Almac Discovery Ltd Pharmaceutical compounds
CN106719769A (zh) * 2016-11-28 2017-05-31 山东农业大学 一种含香菇多糖、苯醚甲环唑和噻虫啉的病虫兼治农药组合物
WO2018133829A1 (zh) 2017-01-23 2018-07-26 南京明德新药研发股份有限公司 作为Wee1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮衍生物
CN108623615A (zh) * 2017-03-23 2018-10-09 上海迪诺医药科技有限公司 吡唑[3,4-d]嘧啶-3-酮的大环衍生物、其药物组合物及应用
US20200108074A1 (en) 2017-03-31 2020-04-09 Seattle Genetics, Inc. Combinations of chk1- and wee1- inhibitors
BR112020002104A2 (pt) * 2017-08-01 2020-08-04 Recurium Ip Holdings, Llc 1,2-dihydro-3h-pyrazolo [3,4-d] pyrimidin-3-one analogs
WO2019037678A1 (zh) * 2017-08-24 2019-02-28 上海迪诺医药科技有限公司 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用
EP3694509A1 (en) 2017-10-09 2020-08-19 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
US20190106427A1 (en) * 2017-10-09 2019-04-11 GiraFpharma LLC Heterocyclic compounds and uses thereof
US20200325145A1 (en) 2017-11-01 2020-10-15 Shijiazhuang Sagacity New Drug Development Co., Ltd. Macrocyclic compound serving as wee1 inhibitor and applications thereof
WO2019096322A1 (zh) * 2017-11-20 2019-05-23 上海医药集团股份有限公司 一种吡唑酮并嘧啶类化合物、其制备方法及应用
WO2019134539A1 (zh) * 2018-01-05 2019-07-11 四川科伦博泰生物医药股份有限公司 二氢吡唑酮并嘧啶类化合物及其制备方法和用途
WO2019165204A1 (en) * 2018-02-23 2019-08-29 Newave Pharmaceutical Inc. 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidine-3-one compounds as inhibitors of wee-1 kinase
CA3089746A1 (en) * 2018-03-09 2019-09-12 Recurium Ip Holdings, Llc Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones
CN108653282B (zh) * 2018-06-28 2020-08-14 中国科学院昆明植物研究所 苯并噻唑类及苯并吡咯类化合物在制备抗肿瘤药物中的应用
WO2020083404A1 (zh) * 2018-10-26 2020-04-30 南京明德新药研发有限公司 作为Wee1抑制剂的嘧啶并吡唑酮类衍生物及其应用
WO2020210320A1 (en) * 2019-04-11 2020-10-15 Recurium Ip Holdings, Llc Substituted l,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
OA7174A (fr) 1981-08-24 1984-04-30 May & Baker Ltd Nouvelles imidazotétrazionones, leur préparation et les médicaments qui les contiennent.
JPH034077B2 (da) 1983-07-14 1991-01-22 Yakult Honsha Kk
IL85035D0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP2628707B2 (ja) * 1987-08-26 1997-07-09 三井石油化学工業株式会社 ピリミジン類及びその薬学的に許容される塩類
US5223608A (en) 1987-08-28 1993-06-29 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
EP0547165B1 (en) 1990-09-28 1999-11-10 Smithkline Beecham Corporation Process for the Preparation of Water-Soluble Camptothecin Analogues, as well as the compounds 10-Hydroxy-11-C(1-6)-alkoxycamptothecin
US5191082A (en) 1990-12-20 1993-03-02 North Carolina State University Camptothecin intermediate and method of making camptothecin intermediates
US5162532A (en) 1990-12-20 1992-11-10 North Carolina State University Intermediates and method of making camptothecin and camptothecin analogs
US5200524A (en) 1990-12-20 1993-04-06 North Carolina State University Camptothecin intermediates and method of making same
US5247089A (en) 1990-12-20 1993-09-21 North Carolina State University Method of making intermediates useful for the manufacture of camptothecin and camptothecin analogs
US5243050A (en) 1990-12-20 1993-09-07 North Carolina State University Alkylpyridone DE ring intermediates useful for the manufacture of camptothecin and camptothecin analogs
SK285035B6 (sk) 1992-10-28 2006-05-04 Genentech, Inc. Antagonisty rastového faktora vaskulárnych endotelových buniek
JP3025602B2 (ja) 1993-05-21 2000-03-27 デビオファーム エス.アー. 光学的に高純度なシス−オキザラート(トランス−l−1,2−シクロヘキサンジアミン)白金(II)錯体の製造方法
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
CA2222231A1 (en) 1995-06-07 1996-12-19 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth of tumors
JP3154399B2 (ja) 1996-07-04 2001-04-09 デビオファーム エス.アー. 白金化合物の製造方法
CZ27399A3 (cs) 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
SE0103649D0 (sv) 2001-11-01 2001-11-01 Astrazeneca Ab Therapeutic quinoline compounds
BR0309783A (pt) 2002-04-26 2005-03-22 Warner Lambert Co Inibidores de quinases de pontos de controlo (wee1 e chk1)
UA80767C2 (en) * 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
BRPI0406809A (pt) * 2003-01-17 2005-12-27 Warner Lambert Co Heterociclos substituìdos de 2-aminopiridina como inibidores da proliferação celular
CA2515132C (en) * 2003-02-07 2012-01-03 Vertex Pharmaceuticals Incorporated Heteroaryl substituted pyrroles useful as inhibitors of protein kinases
US7320992B2 (en) * 2003-08-25 2008-01-22 Amgen Inc. Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
US20050250836A1 (en) 2004-05-03 2005-11-10 Pfizer Inc Inhibitors of checkpoint kinases (Wee1 and Chk1)
PL1775298T3 (pl) 2004-07-01 2013-08-30 Daiichi Sankyo Co Ltd Thienopyrazole derivative showing PDE7 inhibitory activity
US7947695B2 (en) 2005-01-14 2011-05-24 Janssen Pharmaceutica Nv 5-membered annelated heterocyclic pyrimidines as kinase inhibitors
WO2006091737A1 (en) 2005-02-24 2006-08-31 Kemia, Inc. Modulators of gsk-3 activity
PE20080695A1 (es) 2006-04-27 2008-06-28 Banyu Pharma Co Ltd Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel

Also Published As

Publication number Publication date
LT2017278T (lt) 2017-01-25
MA30428B1 (fr) 2009-05-04
RU2008146759A (ru) 2010-06-10
AR060635A1 (es) 2008-07-02
IL194367A (en) 2014-12-31
EP2017278A4 (en) 2009-04-22
EP2017278A1 (en) 2009-01-21
GT200800211A (es) 2009-04-07
US20100063024A1 (en) 2010-03-11
SV2009003060A (es) 2009-04-28
DOP2007000084A (es) 2007-12-31
AU2007244185B2 (en) 2012-10-04
HK1132498A1 (en) 2010-02-26
CR10359A (es) 2009-02-19
TW200811176A (en) 2008-03-01
NO20084968L (no) 2008-11-26
UA96152C2 (xx) 2011-10-10
US8791125B2 (en) 2014-07-29
MX2008013063A (es) 2008-12-16
CN101432284A (zh) 2009-05-13
JPWO2007126128A1 (ja) 2009-09-17
US20070254892A1 (en) 2007-11-01
HUE032987T2 (en) 2017-11-28
US20110189130A1 (en) 2011-08-04
JP5167291B2 (ja) 2013-03-21
US20140303178A1 (en) 2014-10-09
AT475662T (de) 2010-08-15
CN101432284B (zh) 2012-08-15
ES2348751T3 (es) 2010-12-13
EP2016080B1 (en) 2010-07-28
KR101409161B1 (ko) 2014-06-19
DK2017278T3 (da) 2017-02-13
HN2008001532A (es) 2009-06-10
CY1118526T1 (el) 2017-07-12
PT2017278T (pt) 2017-01-03
JP2010132689A (ja) 2010-06-17
JP4513919B2 (ja) 2010-07-28
SI2017278T1 (sl) 2017-05-31
NZ571196A (en) 2011-03-31
US7834019B2 (en) 2010-11-16
MY145408A (en) 2012-02-15
BRPI0710081A2 (pt) 2011-08-02
PE20080695A1 (es) 2008-06-28
EP2017278B1 (en) 2016-11-02
NO341617B1 (no) 2017-12-11
PT2016080E (pt) 2010-10-14
RU2437885C2 (ru) 2011-12-27
WO2007126122A1 (en) 2007-11-08
KR20090017491A (ko) 2009-02-18
DE602007008085D1 (en) 2010-09-09
PL2017278T3 (pl) 2017-10-31
IL194367D0 (en) 2009-08-03
SI2016080T1 (sl) 2011-03-31
US7935708B2 (en) 2011-05-03
TWI409262B (zh) 2013-09-21
PL2016080T3 (pl) 2011-03-31
ES2609087T3 (es) 2017-04-18
CA2650119C (en) 2017-03-14
HRP20100563T1 (xx) 2010-11-30
ECSP088812A (es) 2008-11-27
AU2007244185A1 (en) 2007-11-08
CA2650119A1 (en) 2007-11-08
ZA200807748B (en) 2009-10-28
WO2007126128A1 (ja) 2007-11-08
HRP20161763T1 (hr) 2017-02-24
EP2016080A4 (en) 2009-05-13
EP2016080A1 (en) 2009-01-21

Similar Documents

Publication Publication Date Title
DK2081937T3 (da) Triazolopyridazin-proteinkinasemodulatorer
DK2091663T3 (da) Ultralydsvæskeforstøver
DK2032057T3 (da) Elektrodeindføringsindretning
DK1859712T3 (da) Kapselperforeringsmodul
DK2038356T3 (da) Væskehærdning
DK2076760T3 (da) Fasekontrastafbildning
DK1971249T3 (da) Törreapparat
DK1974615T3 (da) Proteingeldannelse
DK2164844T3 (da) Pyrimidinyl-pyridazinonderivater
DK2209786T3 (da) Pyrimidinsubstituerede purinderivater
DK2121053T3 (da) Metaloxidskeletter
DK2035394T3 (da) 2-pyrazincarboxamidderivater
DK1987346T3 (da) Kuppelgassensor
DK2089364T3 (da) Pyridinonforbindelser
AT540395T (de) Anzeigeansteuersysteme
DE602007002544D1 (de) Nuancierungsmittel
AT505137T (de) Mageninvaginationsvorrichtung
AT465907T (de) Verschlusskappe
AT507122T (de) Wischblatt
AT475662T (de) Dihydropyrazolopyrimidinonderivate
DE602007013937D1 (de) Torantagonisten
DK1862090T3 (da) Interdentalbörste
AT530853T (de) Strahlrohrbratrost
AT457743T (de) Wasserstoffperoxid-zerstäuber
AT546501T (de) Bördelfalzverklebung